1. Introduction {#sec1}
===============

Cardiovascular diseases (CVDs) are the primary public health problem and a chief cause of morbidity and mortality worldwide. Approximately 17.9 million people die from CVDs every year, accounting for 31% of all deaths globally \[[@B1]\]. Coronary atherosclerotic heart disease, also known as coronary heart disease (CHD), is the largest contributor to CVDs due to atherosclerosis (AS), a chronic inflammatory condition of the coronary arterial wall \[[@B2]\]. AS causes cardiovascular stenosis and/or obstruction, further leading to myocardial ischaemia and hypoxia and ultimately giving rise to myocardial necrosis and even cardiac death. Clinically, CHD is divided into chronic coronary artery disease (stable angina) and acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction \[NSTEMI\], ST-segment elevation myocardial infarction \[STEMI\], and sudden coronary death). CHD causes nearly one-third of all deaths globally \[[@B3]\] and is responsible for 15.5 million persons ≥20 years of age having CHD in the United States \[[@B4]\]. In China, the prevalence of CHD surpassed 80 million in 2010, causing death in over one million people every year \[[@B5]\].

It is well known that CHD is considered a common complex multifactorial disease that may be closely associated with environmental, genetic, and other risk factors, such as hypertension, diabetes mellitus, hyperlipidaemia, cigarette smoking, obesity, and so forth \[[@B6], [@B7]\]. Many studies have confirmed that controlling risk factors for CHD can effectively reduce cardiovascular events in both symptomatic and asymptomatic individuals \[[@B8]--[@B10]\]. In the United States, CHD mortality had been increasing since the 1940s until it reached its peak in approximately 1968. However, in recent decades, the death rate from CHD has dropped sharply and decreased by almost half from 1980 to 2000. The main reason may be due to the control of major risk factors and the increased use of evidence-based medical therapies \[[@B8]\]. Moreover, other countries have observed similar decreases in CHD mortality \[[@B9], [@B10]\]. These results underscore the enormous value of primary prevention and evidence-based medical treatments in the management of CHD.

There is ample evidence that dyslipidaemia plays a key role in the development and mortality of CHD \[[@B11]\]. Lowering plasma high cholesterol is an important way to reduce the chances of suffering CHD events. Statins, a common type of lipid-lowering drug, have become the first-line therapy for regulating hyperlipidaemia and CHD risk, making them the most widely used prescription drugs around the word \[[@B12]\]. Statins are a potent competitive inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a regulatory enzyme for cholesterol biosynthesis \[[@B13]\]. Pharmacological studies demonstrated that statins can lower total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) and increase the level of high density lipoprotein cholesterol (HDL-C). Additionally, statins can also inhibit the inflammation reaction, improve endothelial function, and stabilize coronary plaques \[[@B14]\]. Currently, a large number of studies have shown that statins have large secondary prevention effects in patients with CVDs. Simvastatin can decrease the risk of cardiac and all-cause death and the recurrence of myocardial infarction (MI) in patients with CHD \[[@B15]\]. In addition, a systematic review indicated that intensive statin therapy has an excellent effect on lowering the serum lipid level of TC, triglyceride (TG), and LDL-C and on lowering the risk of major adverse cardiac events \[[@B16]\].

However, it is unclear whether statins have similar benefits for individuals without prior CHD. Currently, there are fourteen articles reporting on a similar topic, but most of the studies were associated with primary prevention of CVD. Only two studies were related to CHD, and these two studies were both published in 2000 \[[@B17], [@B18]\]. In addition, some selection biases can be found in the systematic reviews of primary prevention in CVD. Several studies have focused on elderly patients \[[@B19], [@B20]\], and some articles have shown that the study participants had diabetes \[[@B21], [@B22]\]. In addition, a few reviews included trials that partially incorporated patients with a clinical history of CVD \[[@B23]\]. A literature-based meta-analysis showed that statins have limited benefits for all-cause mortality \[[@B24]\], but another study presented the opposite results \[[@B23]\]. All of these findings demonstrate the uncertainty regarding primary prevention of CHD. Thus, the purpose of this study was to reliably determine whether statin therapy can reduce coronary heart events (angina, MI, coronary revascularization, and CHD deaths) among individuals without a history of CHD.

2. Methods {#sec2}
==========

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Supplementary [Material 1](#supplementary-material-1){ref-type="supplementary-material"}).

2.1. Data Source and Search Strategy {#sec2.1}
------------------------------------

We searched PubMed, the Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Scientific Journal Database (VIP) from the inception dates to October 31, 2017. The search strategy used the following general terms individually or combined: "statin", "HMG-CoA", "simvastatin", "fluvastatin", "lovastatin", "pravastatin", "atorvastatin", "rosuvastatin", "coronary", "heart", "angina", "CAD", "CHD", "myocardial infarct^*∗*^", "MI". The detailed search strategy is shown in Supplementary [Material 2](#supplementary-material-1){ref-type="supplementary-material"}. We also checked the reference lists of existing reviews to identify the included studies.

2.2. Study Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------------

We included all randomized controlled trials (RCTs), and the publication language was either English or Chinese. Participants without a clinical history of CHD were included, age and race were not limited. The treatment group was given statins alone or combined with usual care, and the control group was given nothing, placebo, or usual care. Usual care was generally determined based on the specific disease of the participants; for example, patients with diabetes will be given hypoglycaemic agents such as metformin, and patients with hypertension will take captopril or other antihypertensive medicines. If we did not know whether the participants had CHD, these articles were excluded. In addition, we also excluded articles without full text. Moreover, the primary outcomes in this systematic review mainly included angina, nonfatal and/or fatal MI, any coronary heart events, coronary revascularization, and CHD deaths. The secondary outcomes involved any cardiovascular events, CVD deaths and all-cause mortality. We also reported the adverse events, which mainly comprised cancer, diabetes, gastrointestinal/hepatic/renal disorder, myalgia, myopathy, rhabdomyolysis, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), and so forth. The results of the included studies must involve at least one of the primary outcomes.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two authors (Li, X.Y. and Chen, H.Q.) independently conducted the literature search, study selection, and data extraction. The extracted data of the included studies was entered into a standardized table prepared for this review. The extracted data included the first author, publication year, participant types, sample size, sex, age, interventions in the treatment and control groups, dosage of medications, follow-up time, outcomes, and so on. Disagreements were discussed and resolved at a consensus meeting with the corresponding author. In addition, according to the Cochrane Reviewer\'s Handbook, the two authors (Hu, Y.Y. and Zhang, X.T.) individually assessed the risk of bias. Six evaluation criteria for the quality of RCTs were used, which included generation of a random sequence, randomization concealment, blinding method, integrity of the outcome data, selective reporting and other bias. Each quality item was graded as low, unclear or high risk.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We used the Rev Man 5.3 software provided by the Cochrane Collaboration to analyse the data \[[@B25]\]. For continuous variables, the outcomes were described as the weighted mean difference (WMD) and 95% confidence interval (95% CI). For dichotomous variables, the data were expressed as risk ratios (RR) with 95% CIs. Means and standard deviations were calculated for continuous variables, and as for the dichotomous data, we recorded the number of patients in each group who suffered the events. Heterogeneity was assessed using the *χ*^2^ test. If I^2^ \<50%, the statistical heterogeneity was small, and a fixed-effect model was used for the data analysis. If the I^2^ was more than 50%, we performed the subgroup and sensitivity analyses to determine the reason for the heterogeneity, and a random-effects model was conducted. Descriptive analysis was used if the heterogeneity still existed after subgroup and sensitivity analysis. Potential publication bias was assessed using a funnel plot and Begg\'s test when there were more than eight trials in a meta-analysis using Stata 14 software \[[@B26]\]. If P\>0.05, there is no publication bias; if not, publication bias exists.

2.5. GRADE {#sec2.5}
----------

The GRADE approach was used to evaluate the quality of evidence, which was classified as high, moderate, low, or very low based on judgments regarding the risk of bias, inconsistency, indirectness, imprecision, and other considerations \[[@B27]\]. A summary of the findings (SOF) table was prepared using the software program "GRADE pro GDT".

3. Results {#sec3}
==========

3.1. Description of Included Trials {#sec3.1}
-----------------------------------

### 3.1.1. Search Process {#sec3.1.1}

A total of 54820 records were identified by searching the electronic databases, and 23 records were identified from reference lists. After removing 19193 duplicates from the different databases, we evaluated 35650 potentially relevant articles for eligibility. After screening the titles and abstracts, we excluded 30713 studies. Of the 4937 remaining studies, we further excluded 4921 studies after screening the full-text articles. Ultimately, we included 16 studies \[[@B28]--[@B43]\]. The search process and study selection process were shown in [Figure 1](#fig1){ref-type="fig"}, and the characteristics of the included trials were shown in [Table 1](#tab1){ref-type="table"}.

### 3.1.2. Participants {#sec3.1.2}

A total of 69159 participants with no history of CHD were included, and the numbers of participants in the treatment and control groups were 34582 and 34577, respectively. The average sample size of the trial was 4322 participants. The participants in three studies had hypertension \[[@B34], [@B40], [@B43]\], in three studies they had dyslipidaemia \[[@B31], [@B39], [@B41]\], in three studies they suffered cerebrovascular diseases \[[@B28], [@B37], [@B42]\] and in one study they had type 2 diabetes \[[@B30]\]. In addition, the participants in two articles had carotid atherosclerosis/intima thickening and dyslipidaemia \[[@B33], [@B36]\]; in four other studies, the participants exhibited aortic stenosis \[[@B29]\], a high level of hs-CRP \[[@B35]\], a high level of hs-CRP/dyslipidaemia \[[@B32]\], and cerebrovascular diseases/diabetes \[[@B38]\].

### 3.1.3. Interventions {#sec3.1.3}

Most studies compared statins and placebo \[[@B28]--[@B33], [@B35]--[@B38], [@B40], [@B41]\], three articles compared statins plus usual care versus usual care \[[@B34], [@B42], [@B43]\], and only one study compared statins plus diet versus diet \[[@B39]\]. Many stains, such as atorvastatin, lovastatin, rosuvastatin, simvastatin, pravastatin, pravastatin sodium, and so forth, were used in the treatment group, and the dosage of the stains ranged from 5 mg/d to 80 mg/d. The control group medications mainly included hydrochlorothiazide, metformin, captopril, amlodipine, and other antihypertensive, hypoglycaemic, and regulating vascular drugs.

### 3.1.4. Outcomes {#sec3.1.4}

All included studies involved at least one of the primary outcomes, nine studies \[[@B28], [@B30]--[@B32], [@B34], [@B39]--[@B42]\] reported at least one of the secondary outcomes, and seven articles \[[@B28], [@B29], [@B31], [@B34], [@B39]--[@B41]\] reported adverse events.

### 3.1.5. Follow-Up Time {#sec3.1.5}

The shortest follow-up time was 1 year \[[@B35], [@B42], [@B43]\], and the longest follow-up time was an average of 5.3 years \[[@B39]\].

### 3.1.6. Risk of Bias Assessment {#sec3.1.6}

Fourteen studies generated the random sequence by computer or used a random numbers table \[[@B29], [@B30], [@B32]--[@B43]\]. Most studies reported that they carried out double-blind analysis \[[@B28], [@B31]--[@B33], [@B36]--[@B38], [@B40]--[@B42]\], and two articles reported that they used a triple-blind method \[[@B29], [@B30]\]. Two studies reported that the sponsor had no input into the study design and data analysis \[[@B29], [@B40]\]. The Jadad score of all of the studies was more than 3. The risk of bias assessment is shown in [Figure 2](#fig2){ref-type="fig"}.

3.2. Effects of Interventions {#sec3.2}
-----------------------------

### 3.2.1. Primary Outcomes {#sec3.2.1}

*(1) Angina*. Seven trials \[[@B29]--[@B32], [@B35], [@B39], [@B40]\] with 45820 participants, representing 66.25% of the total population, reported angina pectoris. The data was pooled using a fixed-effect model, and no heterogeneity was observed. During the observation period, 184/22886 (0.80%) developed angina in the statin group compared with 263/22934 (1.15%) in the control group. A remarkable difference existed in both groups, and statins exhibited an apparent decrease in the occurrence of angina pectoris (RR=0.70, 95% CI: 0.58\~0.85, I^2^ =0%), as shown in [Figure 3](#fig3){ref-type="fig"}.

*(2) Myocardial Infarction*. Three types of MI were described in the included trials, consisting of nonfatal MI, fatal MI and any MI. In the pooled analysis using a fixed-effect model, eight trials \[[@B28], [@B30], [@B32], [@B33], [@B35], [@B36], [@B39], [@B41]\] with 41191 participants provided strong evidence of a lower recurrence rate of nonfatal MI in the treatment group (RR=0.60, 95% CI: 0.51\~0.69, I^2^ =14%). Only three trials \[[@B30], [@B36], [@B39]\] with 10975 participants reported fatal MI, and the statin group had a slight advantage over the control group (RR=0.49, 95% CI: 0.24\~0.98, I^2^ =0%). In addition, five trials \[[@B29], [@B31], [@B32], [@B39], [@B43]\], including 19602 men and 12992 women, reported the occurrence of any MI. During the observation period, 106/16248 (0.65%) suffered any MI in the treatment group versus 201/16346 (1.23%) in the control group, and the statin group exhibited a lower occurrence of MI (RR=0.53, 95% CI: 0.42\~0.67, I^2^ =0%), as shown in [Figure 4](#fig4){ref-type="fig"}.

*(3) Any Coronary Heart Events*. The category any coronary heart events was defined as CHDs, acute coronary syndrome, or other combinations of coronary events (fatal or nonfatal MI, unstable angina, or sudden cardiac death). Eight trials \[[@B28], [@B31], [@B37]--[@B40], [@B42], [@B43]\] with 37395 participants reported any coronary heart events. The duration ranged from 1 year to a mean follow-up of 5.3 years. The data were analysed using a fixed-effect model, and there was no heterogeneity. The prevalence of coronary heart events in the statin group was 5.98% (1116/18654); in the control group, the prevalence was 8.21% (1538/18741); a total of 2678 participants experienced coronary heart events. There was an evident difference in both groups; therefore, statins can apparently reduce the occurrence of any coronary heart events (RR=0.73, 95% CI: 0.68\~0.78, I^2^ =0%), as shown in [Figure 5](#fig5){ref-type="fig"}.

*(4) Coronary Revascularization*. Thrombolysis, percutaneous coronary intervention (PCI), and coronary artery bypass surgery (CABG) are now collectively known as "coronary revascularization strategy", which provides symptomatic relief and improves long-term outcomes in patients with CHD. It also reveals the severity of coronary artery disease, exhibiting the number of diseased vessels, the site and degree of coronary obstruction, and the status of collateral circulation. There were five studies \[[@B29]--[@B31], [@B39], [@B41]\] reflecting coronary revascularization, and compared with the statin group, participants in the control group suffered more coronary revascularization (1.77% versus 2.69%, RR=0.66, 95% CI: 0.55\~0.78, I^2^ =0%), as shown in [Figure 6](#fig6){ref-type="fig"}.

*(5) CHD Deaths*. Seven trials \[[@B28], [@B29], [@B31], [@B33], [@B34], [@B39], [@B41]\] with 29818 participants reported CHD deaths. During the observation period, 145/14898 (0.97%) participants died of CHD in the statin group compared with 175/14920 (1.17%) in the control group. The data were pooled using a fixed-effect model, and no heterogeneity was observed. The results from the meta-analysis demonstrated that there was no significant difference in CHD deaths between the two groups (RR=0.82, 95% CI: 0.66\~1.02, I^2^ =0%), as shown in [Figure 7](#fig7){ref-type="fig"}.

### 3.2.2. Secondary Outcomes {#sec3.2.2}

*(1) Any Cardiovascular Events*. A total of 3161 participants among a total of 32311 individuals experienced any cardiovascular events in five trials \[[@B28], [@B30], [@B31], [@B39], [@B40]\]; among them, 1372 cases were in the treatment group and 1789 cases were in the control group. The data were analysed using a fixed-effect model, and there was no heterogeneity. Compared with the control group, the statin group showed that statins can effectively reduce the risk of cardiovascular events (RR=0.77, 95% CI: 0.72\~0.82, I^2^ =0%), as shown in [Figure 8](#fig8){ref-type="fig"}.

*(2) CVD Deaths*. Six trials \[[@B28], [@B31], [@B34], [@B39]--[@B41]\] involving 38935 participants, reported CVD deaths. A total of 714 patients suffered CVD deaths, and the numbers of participants in the treatment group and the control group were 331 and 383, respectively. We used a fixed-effect model due to the lower heterogeneity (I^2^ =22%), and the meta-analysis showed that the statin group had a relatively low risk of CVD deaths (RR=0.85, 95% CI: 0.74\~0.99) ([Figure 9](#fig9){ref-type="fig"}). However, this result changed when we applied a random-effects model, and the 95% CI widened until it reached the ineffective line of forest plots (RR=0.85, 95% CI: 0.71\~1.00) ([Figure 10](#fig10){ref-type="fig"}). Thus, some findings warrant further discussion.

*(3) All-Cause Mortality*. Nine trials \[[@B28], [@B30], [@B32], [@B34], [@B37]--[@B42]\] with 53656 participants, representing 77.470% of the total population, reported all-cause mortality. The duration ranged from 1 year to a mean follow-up of 5.3 years. The data were pooled using a random-effects model due to relatively greater heterogeneity. During the study period, 1061/26830 (3.95%) died in the statin group compared with 1173/26826 (4.37%) in the control group. The meta-analysis revealed that there was no significant difference in all-cause mortality between the statin group and the control group (RR=0.88, 95% CI: 076\~1.01, I^2^ =58%), as shown in [Figure 11](#fig11){ref-type="fig"}.

3.3. Adverse Events {#sec3.3}
-------------------

Several trials described adverse events, including cancer, diabetes mellitus, gastrointestinal/hepatic/renal disorder, myalgia, myopathy, rhabdomyolysis, CK, and ALT/AST. As [Figure 12](#fig12){ref-type="fig"} shows, there were no statistically significant differences in the majority of the adverse events except for the change in diabetes. Three studies \[[@B29], [@B32], [@B40]\] reported diabetes mellitus, and the statin group was more prone to this adverse event (RR=1.21, 95% CI: 1.05\~1.39, I^2^ =0%). In addition, compared with the control group, the statin group showed a trend toward renal disorder (RR=1.12, 95% CI: 1.00\~1.26, I^2^ =0%) and ALT/AST elevation (RR=2.36, 95% CI: 1.00\~5.60, I^2^ =73%).

3.4. Publication Bias {#sec3.4}
---------------------

Potential publication bias was assessed using a funnel plot and Begg\'s test in Stata 14 software when more than eight trials were included in a meta-analysis. Thus, we evaluated the publication bias for nonfatal MI, any coronary heart events, and all-cause mortality. Funnel plot analysis showed that there was no evidence of publication bias, and Begg\'s test revealed all P values \>0.05, as shown in Figures [13(a)](#fig13){ref-type="fig"}-[13(c)](#fig13){ref-type="fig"}.

3.5. GRADE {#sec3.5}
----------

The quality of evidence was evaluated by the GRADE approach, and most cardiac events had moderate scores. Some outcomes exhibited low evidence due to wide confidence intervals; the GRADE quality of summary evidence is shown in [Table 2](#tab2){ref-type="table"}.

4. Discussion {#sec4}
=============

In these meta-analyses from 16 studies with 69159 participants without a history of CHD, we found that statins can effectively decrease the occurrence of angina, nonfatal and/or fatal MI, any coronary heart events, coronary revascularization and any cardiovascular events. However, based on the current evidence, there were no significant differences in CHD deaths and all-cause mortality between the statin group and control group, and the results for CVD deaths remained controversial. In addition, we analysed the relevant adverse events described in the included studies and found that statin therapy can cause diabetes and increase the trend toward renal disorder and ALT/AST elevation.

Different follow-up time may affect the event outcomes. To verify the effect of follow-up time on the event outcomes, we performed a subgroup analysis of follow-up time. Sixteen RCTs were included in this review. The follow-up time ranged from 1 year to 5.3 years, and the median follow-up was 3.4 years. Thus, we divided the follow-up time into two periods (follow-up \<3.4 years; follow-up \>3.4 years) for subgroup analysis. We could not perform the subgroup analysis for some primary and secondary outcomes, such as coronary revascularization, CHD deaths, any cardiovascular events and CVD deaths, because no studies or only one study of these outcomes tracked patients for less than 3.4 years. Thus, we conducted a subgroup analysis of the occurrence of angina, nonfatal myocardial infarction, any myocardial infarction, any coronary heart events and all-cause mortality. These results suggested that the length of follow-up may not be a major factor influencing the event outcomes, as shown in Supplemental [material 3](#supplementary-material-1){ref-type="supplementary-material"} (Supplement [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}-[5](#supplementary-material-1){ref-type="supplementary-material"}). There were two possible reasons for these results. First, in this review, the shortest follow-up was 1 year, while we thought 1 year was a relatively long follow-up time. Second, the follow-up time in this review varied from 1 year to 5.3 years, and we thought that the follow-up gap was not very significant.

As for all-cause mortality in participants without previous CVDs, one study \[[@B24]\] did not find evidence that statin therapy is beneficial in high-risk primary prevention, but the other article \[[@B23]\] reported the opposite results. Our meta-analysis showed that there were no significant differences in CHD deaths and all-cause mortality among participants without a history of CHD, and the conclusion regarding CVD deaths remained controversial. There may be two reasons: on the one hand, statins have a limited impact on mortality; on the other hand, based on current evidence, there is not enough time to observe the death rate. After all, the length of follow-up for this review ranged from 1-year to 5.3 years, and it may take longer to observe participants from no CHD to death.

Many articles have reported that statins exhibit more adverse events \[[@B44]\]. In our review, there was no statistical significance in cancer, gastrointestinal/hepatic/renal disorder, muscular toxicity, and CK elevation between the two groups, but statins exhibited a higher incidence rate of diabetes mellitus. In addition, compared with the control group, the statin group showed a trend toward renal disorder and ALT/AST elevation. These adverse events will cause some patients to stop using statins. However, a cohort study has demonstrated that continued statin prescription after adverse events can lower the incidence of death and cardiovascular events \[[@B45]\]. Thus, the advantages of statins exceed their disadvantages. There are two aspects that may be considered to reduce adverse events. On the one hand, previous studies reported that lipophilic rather than hydrophilic statins easily contributed to cytotoxicity, and this relationship did not correlate with cholesterol-lowering effects \[[@B46]--[@B48]\]. Therefore, it is vital to select the appropriate statins according to clinical experience. On the other hand, the study showed that high-dose statins may be beneficial to improve cardiac events, but they also increased the risk of side effects \[[@B49]\]. Nevertheless, some articles presented the opposite conclusion \[[@B50], [@B51]\]. Thus, a reasonable dose for statins should be chosen based on individual differences.

5. Limitations {#sec5}
==============

Most studies did not describe statistical blinding and the role of sponsors in data processing, which was the main methodological omission. In addition, there were not enough studies involving the dose-effect relationship of statins. The participants in the included studies came from America, Canada, China, Japan, the United Kingdom, Ireland and so forth; participants from Africa and South America were lacking. We only included studies in which the language was English or Chinese. In addition, it is a fact that some factors will affect this review\'s conclusions, such as the inclusion of participants with other diseases (hypertension, dyslipidaemia, cerebrovascular diseases, diabetes, etc.), the use of multiple types and various doses of statins and so forth; all of these easily could have caused inaccuracies in the outcomes.

6. Future Directions {#sec6}
====================

Given the available evidence in our work, the results of this review suggested that statins alone or combined with usual care exhibited a specific advantage in the primary prevention of angina and nonfatal and/or fatal MI as well as any coronary heart events. When participants have cardiovascular risk factors, active statin therapy plays a crucial role in preventing the occurrence and improving the prognosis of coronary heart events. For consequent incidental adverse events, it is vital to choose appropriate statins and a reasonable dose of statins based on clinical experience and individual patient differences rather than stop the use of statins. In addition, trials of statins should be performed on all continents around the world to fully reflect the efficacy of statins in all aspects. All studies must report the role of sponsors; after all, this will cause reporting bias.

7. Conclusion {#sec7}
=============

Statins seemed beneficial for primary prevention of coronary heart events in participants without evidence of CHD, but there were no statistical differences in CHD deaths and all-cause mortality.
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###### 

The characteristics of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Participants                                         Sample (T/C)   Gender (M: F) (T/C)   Age, mean (SD) (T/C)   Intervention (T/C)                    Duration    Outcomes
  ---------------------------------- ---------------------------------------------------- -------------- --------------------- ---------------------- ------------------------------------- ----------- ------------
  Amarenco et al., 2006 \[[@B28]\]   TIA or stroke                                        2365/2366      1427:938/1396:970     63.0±0.2/62.5±0.2      Atorvastatin (80 mg/d)/Placebo        4.9 years   ②⑤⑦⑧⑨⑩⑪

  Chan et al., 2010 \[[@B29]\]       Aortic stenosis                                      134/135        81:53/85:50           58.0±12.9/57.9±14.3    Rosuvastatin (40 mg/d)/Placebo        3.5 years   ①④⑥⑦⑪

  Colhoun et al., 2004 \[[@B30]\]    Type 2 diabetes                                      1428/1410      972:456/957:453       61.5±8.3/61.8±8.0      Atorvastatin (10 mg/d)/Placebo        3.9 years   ①②③⑥⑧⑩

  Downs et al., 1998 \[[@B31]\]      Dyslipidaemia                                        3304/3301      2805:499/2803:498     58±7/58±7              Lovastatin (20-40 mg/d)/Placebo       5.2 years   ①④⑤⑥⑦⑧⑨⑪

  Fonseca et al., 2009 \[[@B32]\]    LDL-C\<130 mg/dL and\                                8901/8901      5475:3426/5526:3375   66.0/66.0              Rosuvastatin (20 mg/d)/Placebo        1.9 years   ①②④⑩
                                     hsCRP≥2.0 mg/L                                                                                                                                                     

  Furberg et al., 1994 \[[@B33]\]    Carotid atherosclerosis and\                         460/459        241:219/232:227       61.80/61.65            Lovastatin (20-40 mg/d)/Placebo       33-month    ②⑦
                                     Dyslipidaemia                                                                                                                                                      

  Han et al., 2017 \[[@B34]\]        Hypertension                                         1467/1400      763:704/689:711       71.3±5.2/71.2±5.2      Pravastatin sodium (40 mg/d)/UC       4.8 years   ⑦⑨⑩⑪

  Huang et al., 2012 \[[@B35]\]      High level of Hs-CRP                                 85/84          35:50/36:48           58±4/59±5              Rosuvastatin (5 mg/d)/Placebo         1-year      ①②

  Mercuri et al., 1996 \[[@B36]\]    Carotid intima thickening and hypercholesterolemia   151/154        85:66/79:75           54.9±5.99/55.1±6.00    Pravastatin (40 mg/d)/Placebo         3 years     ②③

  Mok et al., 2009 \[[@B37]\]        Asymptomatic middle cerebral artery stenosis         113/114        74:153                63.0±14.0              Simvastatin (20 mg/d)/ Placebo        2 years     ⑤⑩

  MRC/BHF, 2002 \[[@B38]\]           Diabetes and cerebrovascular disease                 3575/3575      Unclear               Unclear                Simvastatin (40 mg/d)/Placebo         5 years     ⑤

  Nakamura et al., 2006 \[[@B39]\]   Hypercholesterolemia                                 3866/3966      1528:2338/1248:2718   58.2±7.3/58.4±7.2      Pravastatin (10-20 mg/d) +Diet/Diet   5.3 years   ①②③④⑤⑥⑧⑨⑩⑪

  Sever et al., 2003 \[[@B40]\]      Hypertension                                         5168/5137      4189:979/4174:963     63.1±8.5/63.2±8.2      Atorvastatin (10 mg/d)/Placebo        3.3 years   ①⑤⑧⑨⑩⑪

  Shepherd et al., 1995 \[[@B41]\]   Hypercholesterolemia                                 3302/3293      All the men           55.3±5.5/55.1±5.5      Pravastatin (40 mg/d)/Placebo         4.9 years   ②⑥⑦⑨⑩⑪

  Zhai et al., 2009 \[[@B42]\]       TIA                                                  220/239        158:62/169:70         63.2±12.4              Atorvastatin (60 mg/d) + UC/UC        1-year      ⑤⑩

  Zhang et al., 2016 \[[@B43]\]      Hypertension                                         43/43          51:35                 58.62 ±3.05            Atorvastatin (20 mg/d) + UC/UC        1-year      ④⑤
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: TIA: transient ischaemic attack; LDL-C: low density lipoprotein-cholesterol; hsCRP: hypersensitive C-reactive protein; UC: usual care; ①angina; ②nonfatal MI; ③fatal MI; ④any MI; ⑤coronary heart disease; ⑥coronary revascularization; ⑦CHD deaths; ⑧any cardiovascular event; ⑨CVD deaths; ⑩all-cause mortality; ⑪adverse reactions.

###### 

GRADE quality of evidence summary table.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                     Illustrative comparative risks^*∗*^ (95% CI)   Relative effect (95% CI)   No. of participants   \   Quality of   \
                                                                                                         (studies)                 the evidence   \
                                                                                                                                   (GRADE)
  ---------------------------- ---------------------------------------------- -------------------------- ------------------------- ------------------
  Angina                       Study population                               RR 0.7                     45820                     ⊕⊕⊕* *⊝

  11 per 1000                  8 per 1000 (7 to 10)                           (0.58 to 0.85)             (7 studies)               moderate^1^

  Moderate                                                                                                                         

  14 per 1000                  10 per 1000 (8 to 12)                                                                               

  Non-fatal MI                 Study population                               RR 0.60                    41191                     ⊕⊕⊕* *⊝

  21 per 1000                  12 per 1000 (11 to 14)                         (0.51 to 0.69)             (8 studies)               moderate^1^

  Moderate                                                                                                                         

  21 per 1000                  13 per 1000 (11 to 14)                                                                              

  Fatal MI                     Study population                               RR 0.49                    10975                     ⊕⊕⊕* *⊝

  4 per 1000                   2 per 1000 (1 to 4)                            (0.24 to 0.98)             (3 studies)               moderate^1^

  Moderate                                                                                                                         

  1 per 1000                   0 per 1000 (0 to 1)                                                                                 

  Any MI                       Study population                               RR 0.53                    32594                     ⊕⊕⊕* *⊝

  12 per 1000                  7 per 1000 (5 to 8)                            (0.42 to 0.67)             (5 studies)               moderate^1^

  Moderate                                                                                                                         

  22 per 1000                  12 per 1000 (9 to 15)                                                                               

  Any coronary heart events    Study population                               RR 0.73                    37395                     ⊕⊕⊕* *⊝

  82 per 1000                  60 per 1000 (56 to 64)                         (0.68 to 0.78)             (8 studies)               moderate^1^

  Moderate                                                                                                                         

  67 per 1000                  49 per 1000 (46 to 52)                                                                              

  Coronary revascularization   Study population                               RR 0.66                    24139                     ⊕⊕⊕* *⊝

  27 per 1000                  18 per 1000 (15 to 21)                         (0.55 to 0.78)             (5 studies)               moderate^1^

  Moderate                                                                                                                         

  24 per 1000                  16 per 1000 (13 to 19)                                                                              

  CHD deaths                   Study population                               RR 0.82                    29818                     ⊕⊕⊕* *⊝

  12 per 1000                  10 per 1000 (8 to 12)                          (0.66 to 1.02)             (7 studies)               moderate^1^

  Moderate                                                                                                                         

  16 per 1000                  13 per 1000 (11 to 16)                                                                              

  Any cardiovascular events    Study population                               RR 0.77                    32311                     ⊕⊕⊝* *⊝

  111 per 1000                 85 per 1000 (80 to 91)                         (0.72 to 0.82)             (5 studies)               low^1,2^

  Moderate                                                                                                                         

  95 per 1000                  73 per 1000 (68 to 78)                                                                              

  CVD deaths                   Study population                               RR 0.85                    38935                     ⊕⊕⊕* *⊝

  20 per 1000                  17 per 1000 (15 to 19)                         (0.74 to 0.99)             (6 studies)               moderate^1^

  Moderate                                                                                                                         

  19 per 1000                  16 per 1000 (14 to 19)                                                                              

  All-cause mortality          Study population                               RR 0.88                    53656                     ⊕⊕⊕* *⊝

  44 per 1000                  38 per 1000 (33 to 44)                         (0.76 to 1.01)             (9 studies)               moderate^1^

  Moderate                                                                                                                         

  41 per 1000                  36 per 1000 (31 to 41)                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^ The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; RR: Risk ratio.

GRADE Working Group grades of evidence.

High quality: further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: we are very uncertain about the estimate.

^1^The random sequence generation, allocation concealment, and blinding in some studies were not clear.^2^The confidence interval was wide.

[^1]: Academic Editor: Claudio De Lucia
